Optimization for Regorafenib in HCC

Summary

This is a randomized, two arm, phase II study of 1st Cycle dose optimization for regorafenib treatment compared to standard dose of regorafenib treatment in HCC patients for whom the physician is intending to treat with regorafenib and who failed any 1st line systemic treatment.

Timeline

Start

2021-01-21

Primary completion

2021-10-13

Completion

2021-12-10

Outcome

Outcome not reported

Stopped (Enrollment): “Enrollment rate not sufficient to meet funding entity's corporation timeline expectations, entity terminated study's fiscal support. Termination decision was purely administrative in nature and did not involve drug or patient safety issues.”

Drugs

Indications